Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2006

View Archived Issues

Phase I data on RC-1291, a ghrelin mimetic targeted for cancer cachexia

AEterna Zentaris report on novel peptidomimetic GnRH antagonist

Pfizer reports on weekly rhGh injection

Barr submits regulatory filings for acquisition of Pliva

Avicena studies ALS-08 combination therapies for ALS

Noopept shows therapeutic potential for Alzheimer's disease

Japanese agreement signed for Zevalin

DL-06001 and DL-06002 studied for symptoms of Parkinson's disease

Phase III study of TH-9507 for HIV-associated lipodystrophy cleared to continue

Phase Ib study investigates Reolysin/radiation therapy in advanced cancers

Novozymes acquires Delta Biotechnology

Sanctura XR reduces overactive bladder symptoms with good tolerability

DMXB-A improves neurocognition in schizophrenia patients

Phase I results encouraging with EKB-569 in advanced cancer patients

Pirfenidone pharmacokinetics assessed in rats, dogs and humans

Intraarticular steroids beneficial in hip osteoarthritis

Cook's Zilver stent approved for vascular use

MabThera approved for rheumatoid arthritis in Europe

European approval for MabThera as maintenance therapy in NHL

Pharmacokinetic profile of Huperzine A prodrug ZT-1 reported

Selective ACAT1 inhibitor shows plaque-stabilizing activity in a mouse model of atherosclerosis

New therapeutic agents for HIV infection disclosed in recent patents

Novel PPAR ligands for dermatological disorders described in recent Galderma patent

New coagulation factor Xa inhibitors prepared and tested

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...